Laboratory News and Research

RSS

ELLICSR research centre opened at UHN

What do you get when you combine a comedian, a magician, a radio show host, and a chef? A group of cancer survivors and caregivers celebrating National Cancer Survivors Day at the opening of a unique new research centre at University Health Network (UHN), the first of its kind in Canada.

4 Jun 2010

WHO says H1N1 remains pandemic

WHO Director-General Margaret Chan on Thursday announced the WHO still considers H1N1 (swine) flu a pandemic, despite the fact "its most intense activity has passed in many parts of the world," Reuters reports (Lynn, 6/3).

4 Jun 2010

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.

4 Jun 2010

Nutrient found in maternal diet provide lasting cognitive, emotional benefits to people with Down syndrome: Study

A nutrient found in egg yolks, liver and cauliflower taken by mothers during pregnancy and nursing may offer lifelong "dramatic" health benefits to people with Down syndrome.

4 Jun 2010

New pricing of $19,500 set for Illumina's individual genome sequencing service

Illumina, Inc. today announced a new price of $19,500 for its individual genome sequencing service. In addition, the company announced a price of $14,500 per genome for groups of five or more participants using the same physician. Individuals with serious medical conditions for whom whole-genome sequencing could provide potential direct clinical value will be eligible for special pricing of $9,500 per genome.

From Illumina, Inc. 4 Jun 2010

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

3 Jun 2010

New approach to treat RA can change lives of millions of patients: Research

Portuguese scientists have just published a revolutionary new approach to treat rheumatoid arthritis (RA) which, if translated to humans, can change the way we treat autoimmunity (and so diseases like RA but also diabetes and MS) and, with it, the lives of millions of patients.

3 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

Extracts from peach and plum kill breast cancer cells, say AgriLife Research scientists

Breast cancer cells - even the most aggressive type - died after treatments with peach and plum extracts in lab tests at Texas AgriLife Research recently, and scientists say the results are deliciously promising. Not only did the cancerous cells keel over, but the normal cells were not harmed in the process.

3 Jun 2010

Chili peppers may cause weight loss and fight fat buildup, says study

Scientists are reporting new evidence that capsaicin, the stuff that gives chili peppers their kick, may cause weight loss and fight fat buildup by triggering certain beneficial protein changes in the body. Their study, which could lead to new treatments for obesity, appears in ACS' monthly Journal of Proteome Research.

3 Jun 2010

Life Technologies makes equity investment in SGI

Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has made an equity investment in Synthetic Genomics, Inc., a privately held company founded to commercialize synthetic genomic advances. Terms of the investment were not disclosed.

3 Jun 2010

Light therapy may be alternative treatment for prostate cancer

Cliff Berkman is working on a better way—one that specifically targets prostate cancer cells and causes a type of natural death that spares surrounding tissues from damage.

3 Jun 2010

Novel anti-malarial drug developed from blood thinner by Australian scientists

Malaria caused by a parasite that is borne in female mosquitoes and that spreads in humans through mosquito bites is a major public health problem and it kills more than a million people world wide each year. With the rise of resistance of many of the strains of the malaria parasite to most of the anti-malarial drugs the problem is escalating at an alarming pace.

2 Jun 2010

Cantel Medical acquires Texas-based Purity Water

CANTEL MEDICAL CORP., through its Mar Cor Purification subsidiary, has continued the expansion of its water purification and filtration segment by purchasing Texas-based Purity Water Company of San Antonio, Inc. Purity provides water treatment equipment and services for laboratory, industrial, medical, pharmaceutical and semiconductor customers in Texas and neighboring states. The acquired business had pre-acquisition revenues of approximately $3.0 million.

2 Jun 2010

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The "For Investigational Use Only" laboratory-based testing service uses Chronix's breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases.

2 Jun 2010

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

An enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis -- cathepsin K -- eluded reliable detection in laboratory experiments in the past. Now, a research team at the Georgia Institute of Technology has developed an assay that reliably detects and quantifies mature cathepsin K using a technique called gelatin zymography.

2 Jun 2010

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Cancer diagnostics company Biomoda, Inc. and Obio, a corporation formed to pursue public and private funding for cancer research in Ohio, signed a memorandum of understanding to establish a CLIA-certified Biomoda clinical laboratory in Ohio to support ongoing research and development on Biomoda's porphyrin-based assay for the detection of early-stage cancer.

2 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

LAB Research's Canadian laboratory receives OECD-GLP compliance status

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that its Canadian laboratory has received a Good Laboratory Practices recognition from the Standards Council of Canada.

2 Jun 2010

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

The University of Minnesota and Mayo Clinic, under the mantle of the Minnesota Partnership for Biotechnology and Medical Genomics, have formed a strategic research relationship with the Karolinska Institute of Stockholm, Sweden, the top-rated medical research university in Europe. Leaders of each institution signed memoranda of understanding to commit to the formal ongoing collaboration, called the Frontiers of Biomedical Research.

2 Jun 2010

Laboratory News and Research

ELLICSR research centre opened at UHN

WHO says H1N1 remains pandemic

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Nutrient found in maternal diet provide lasting cognitive, emotional benefits to people with Down syndrome: Study

New pricing of $19,500 set for Illumina's individual genome sequencing service

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

New approach to treat RA can change lives of millions of patients: Research

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

Extracts from peach and plum kill breast cancer cells, say AgriLife Research scientists

Chili peppers may cause weight loss and fight fat buildup, says study

Life Technologies makes equity investment in SGI

Light therapy may be alternative treatment for prostate cancer

Novel anti-malarial drug developed from blood thinner by Australian scientists

Cantel Medical acquires Texas-based Purity Water

Chronix Biomedical to launch new disease detection, monitoring service for cancer researchers at 2010 ASCO

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

LAB Research's Canadian laboratory receives OECD-GLP compliance status

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

Lab Diagnostics and Automation - Third Edition eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo